All In Biotech

Drug Trial Radar · NCT01359592

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

159

Actual

Start

Sep 2011

Primary completion

Jun 3, 2020

Study completion Dec 2023

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
May 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.

Conditions

  • Lymphoma

Interventions

  • rituximabBiological

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • prednisoneDrug

  • vincristine sulfateDrug

  • R-CHOP regimenOther

  • laboratory biomarker analysisOther

  • fludeoxyglucose F 18Radiation

  • selective external radiation therapyRadiation

  • yttrium Y 90 ibritumomab tiuxetanRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)Time frame: up to 5 years

Locations

240 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Center

    Anchorage, Alaska

  • Arizona Cancer Center at University of Arizona Health Sciences Center

    Tucson, Arizona

  • Aurora Presbyterian Hospital

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado

  • St. Anthony Central Hospital

    Denver, Colorado

  • Kaiser Permanente - Denver

    Denver, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado

  • St. Joseph Hospital

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

    Grand Junction, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • Kaiser Permanente - Lafayette

    Lafayette, Colorado

  • Littleton Adventist Hospital

    Littleton, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Hope Cancer Care Center at Longmont United Hospital

    Longmont, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • Parker Adventist Hospital

    Parker, Colorado

  • St. Mary - Corwin Regional Medical Center

    Pueblo, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • Exempla Lutheran Medical Center

    Wheat Ridge, Colorado

  • Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

    Hartford, Connecticut

  • Yale Cancer Center

    New Haven, Connecticut

  • Piedmont Hospital

    Atlanta, Georgia

  • Northside Hospital Cancer Center

    Atlanta, Georgia

  • Saint Joseph's Hospital of Atlanta

    Atlanta, Georgia

  • CCOP - Atlanta Regional

    Atlanta, Georgia

  • WellStar Cobb Hospital

    Austell, Georgia

  • John B. Amos Cancer Center

    Columbus, Georgia

  • Charles B. Eberhart Cancer Center at DeKalb Medical Center

    Decatur, Georgia

  • Piedmont Fayette Hospital

    Fayetteville, Georgia

  • Gwinnett Medical Center

    Lawrenceville, Georgia

  • Kennestone Cancer Center at Wellstar Kennestone Hospital

    Marietta, Georgia

  • Southern Regional Medical Center

    Riverdale, Georgia

  • Harbin Clinic Cancer Center - Medical Oncology

    Rome, Georgia

  • Kapiolani Medical Center at Pali Momi

    ‘Aiea, Hawaii

  • Oncare Hawaii, Incorporated - Pali Momi

    ‘Aiea, Hawaii

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.